Overview of Inapsine

Property	Description
Active ingredient	Droperidol
Form	Injectable solution (Parenteral)
Pharmacological class	Neuroleptic Agent, Antiemetic Agent
General purpose	Tranquilization and prevention of nausea/vomiting
Origin	Synthetic organic compound

What Type of Drug is Inapsine (Droperidol)?

Inapsine is the trade name for the active, synthetic compound Droperidol, a medication formally classified as both a Neuroleptic Agent and a strong Antiemetic Agent. Its unique chemical structure, a Butyrophenone derivative, places it among a class of powerful agents recognized for their substantial influence on the central nervous system (CNS). This dual pharmacological classification is clinically recognized for its ability to modify nerve function to induce tranquility while simultaneously suppressing signals that cause the urge to vomit. Unlike many single-action sedatives or antiemetics, Droperidol provides both effects concurrently.

Composition and General Purpose of Inapsine

This medication is supplied exclusively as an injectable solution, which dictates its parenteral route of administration in clinical settings, ensuring rapid onset and controlled delivery. The solution contains the active ingredient Droperidol, prepared in a sterile aqueous solution (water for injection) to maintain stability and compatibility with bodily fluids. The general purpose of administering Inapsine is two-fold: it is utilized to induce a state of profound tranquilization and sedation, often required to manage agitation during acute medical or diagnostic procedures, and to provide reliable relief from feelings of nausea and vomiting (N/V). The drug's capacity for effective stabilization of acutely distressed patients is a distinctive feature, particularly when immediate pharmacological intervention is necessary, such as in the context of procedural care.

Regulatory References

Droperidol Injection Label (DailyMed)

What side effects are possible with Inapsine?

Possible side effects and safety information

The official safety documentation for Inapsine (droperidol), a neuroleptic and antiemetic agent, is organized around risks classified by frequency and system involvement, focusing on critical cardiac and central nervous system effects.

Serious Adverse Reactions and Cardiac Risk

Regulatory agencies explicitly document the potential for QT interval prolongation, a cardiac conduction abnormality that can lead to fatal arrhythmias, specifically Torsades de pointes (TdP), Ventricular Tachycardia, and Cardiac Arrest. This critical risk is often highlighted in official labeling, defining the drug's safety profile and leading to its restricted use. Another rare but serious reaction is Neuroleptic Malignant Syndrome (NMS), a severe, potentially fatal syndrome associated with this pharmacological class.

Commonly Documented Adverse Reactions

The more frequently observed adverse reactions are categorized within the Nervous System and Vascular Disorders. Common effects include Drowsiness and Sedation, reflecting the drug's tranquilizing properties. Hypotension (low blood pressure) is another frequently reported vascular effect. Patients may also experience Anxiety, Restlessness (Akathisia), or Dysphoria.

Population-Specific Safety Constraints

Use of Inapsine is strictly contraindicated in patients with known or suspected prolonged QT intervals or congenital long QT syndrome. Caution is also advised for use in older adults, where lower dosing may be necessary. Furthermore, the safety and efficacy have not been established in children younger than two years of age according to regulatory documents.

Overdose and Emergency Response

The official overdose profile for Droperidol is defined as an extension of its known pharmacological actions, primarily affecting the central nervous and cardiovascular systems.

Documented Overdose Manifestations

Overdose manifestations are officially documented to include profound central nervous system (CNS) depression, such as psychic indifference, unusual drowsiness, and potential hypoventilation or apnea. Dose-related toxicity may result in convulsions. Other signs include cardiovascular changes like hypotension and tachycardia, alongside significant extrapyramidal symptoms, such as muscle rigidity and uncontrolled movements.

When to Seek Urgent Medical Help

Regulatory guidance mandates that individuals seek immediate medical attention upon the suspicion of overdose. This is due to the documented risk of severe, life-threatening complications, including QT interval prolongation, Torsade de Pointes, ventricular arrhythmias, and the potential for cardiac arrest and sudden death.

Management and Monitoring

Treatment is symptomatic and supportive, as no specific antidote is known. Emergency procedures required by regulatory labels include maintaining a patent airway and providing assisted or controlled respiration. If severe hypotension occurs, management involves considering hypovolemia and administering parenteral fluid therapy. Due to cardiac risk, the patient must be carefully observed for 24 hours with close monitoring for signs of QT interval prolongation.

Therapeutic Uses of Inapsine

Inapsine (droperidol) is a medication utilized in specialized clinical settings to help manage symptoms associated with surgical and diagnostic procedures. Its primary approved use is to reduce the incidence of nausea and vomiting that may occur during the perioperative period, which includes the time surrounding surgery. The goal of this treatment is to support patient comfort and recovery.

Quick Fact: Relief for Nausea and Vomiting

Additionally, this agent is employed to assist in providing tranquilization and managing apprehension in patients undergoing medical interventions. This supportive function helps professionals address immediate symptomatic needs in a controlled environment. The medication is an option in therapeutic choices for patients who may not have responded to other adequate treatments.

Eligibility and Restrictions for Use

Inapsine (droperidol) eligibility is strictly defined by regulatory documents, particularly regarding cardiac health, age, and neurological status. The medicine's use is subject to the following official population rules:

Population	Status	Condition
Children	Not Recommended	Under 2 years; safety and efficacy have not been established.
Older Adults	Caution/Restricted	Over 65 years; requires an appropriately reduced initial dose.
Pregnant/Nursing	Restricted	Pregnancy Category C; repeat administration not recommended during lactation.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with known or suspected congenital long QT syndrome or a QTc interval that is already prolonged (>440 msec in males or >450 msec in females). Contraindication also applies to individuals with clinically significant bradycardia, Parkinson's Disease, severe depression, Phaeochromocytoma, or known hypersensitivity to any butyrophenone derivative.

Conditional and Restricted Use

Use is reserved only for patients who have failed to respond to adequate alternative treatments due to the potential for serious proarrhythmic effects. Patients with hepatic or renal impairment or those with risk factors for QT prolongation (e.g., electrolyte imbalances) require extreme caution and a reduced initial dose as stated in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Inapsine ( Droperidol)

Classification	Official Regulatory Documentation
Interaction severity classification	Contraindicated (with QT prolonging agents), Use with Caution (with CNS depressants, CYP inhibitors, and electrolyte-altering drugs).
Interaction-context constraints	Interactions are primarily constrained by the risk of cardiotoxicity (QT prolongation) and excessive sedation (CNS depression).

Official Interaction Statements

Contraindicated Combinations: Droperidol is formally prohibited for co-administration with any medicinal product that is known to prolong the QT interval, such as Class I and Class III antiarrhythmics, due to the high risk of additive cardiotoxicity.
Central Nervous System (CNS) Depressants: Co-administration with other CNS depressants, including opioids and general anesthetics, results in additive pharmacological effects that may necessitate a reduction in the dose of the other agent to avoid excessive sedation.
Metabolic Pathway: Droperidol is primarily metabolized by the cytochrome P450 isoenzymes CYP1A2 and CYP3A4. The label notes that inhibitors of these enzymes may reduce Droperidol clearance, potentially prolonging its effects.
Electrolyte-Altering Agents: Drugs that can cause hypokalemia or hypomagnesemia (such as certain diuretics) may indirectly increase the risk of QT prolongation when combined with Droperidol.
Dopamine Agonists: Droperidol may cause pharmacodynamic antagonism of the therapeutic effects of Dopamine Agonists, such as Levodopa.
Alcohol: Consumption of alcohol is documented to enhance the CNS depressant effects of Droperidol.

These officially stated interaction patterns govern the use of Droperidol when combined with other substances, with mandatory absolute prohibitions related to cardiotoxicity risk and management constraints regarding co-administered CNS depressants.

Mechanism of Action

Inapsine (droperidol) functions as a butyrophenone neuroleptic primarily through antagonism of dopamine D2 receptors in the central nervous system. This receptor blockade is prominent in subcortical brain regions, including the mesolimbic and chemoreceptor trigger zone (CTZ) pathways.

By competitively binding to D2 receptors, Inapsine prevents the endogenous neurotransmitter dopamine from activating these G protein-coupled receptors. This action decreases dopaminergic neurotransmission. The D2 receptor antagonism in the CTZ modulates afferent signaling to the vomiting center. Additionally, Inapsine exhibits antagonistic activity at alpha1-adrenergic receptors and, to a lesser extent, certain serotonin receptors (specifically 5-HT2). The alpha1-adrenergic antagonism leads to an inhibitory effect on vascular tone regulation, resulting in a decrease in systemic vascular resistance. Furthermore, the drug can influence cardiac electrical activity by interaction with the potassium channels responsible for repolarization, specifically those mediating the rapid component of the delayed rectifier potassium current ( I Kr), which contributes to the observed QT interval prolongation on the electrocardiogram.

Dosage and Administration Information

Official Administration Guidelines for Inapsine (Droperidol)

Inapsine is administered only by a healthcare professional via intramuscular (IM) injection or slow intravenous (IV) injection. The dosage must be individualized based on factors such as age, body weight, physical status, and concurrent medications. Routine monitoring of vital signs and an electrocardiogram (ECG) is required during administration. Parenteral products must be visually inspected for particulate matter or discoloration prior to use; if observed, the product must not be administered.

Age Group	Maximum Recommended Initial Dose	Additional Dosing Rule
Adults	2.5 mg IM or slow IV	1.25 mg may be administered with caution and only if potential benefit outweighs risk.
Children (2 to 12 years)	0.1 mg/kg IM or slow IV	Administer additional doses with caution and only if potential benefit outweighs risk.
Geriatric Patients	Consider a reduced initial dose with careful titration	Administer additional doses with caution and only if potential benefit outweighs risk.

For intravenous administration, the injection should be administered slowly over at least one minute. The product is not typically associated with specific timing instructions related to meals. This medication is intended for single, acute use in a medical setting, and instructions for missed doses are not applicable to its official protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Inapsine

Evidence for Use in Preventing Nausea and Vomiting After Surgery (PONV)

Research examined Inapsine in contexts related to feelings of physical discomfort that was observed after surgical procedures, specifically nausea and vomiting. The most common types of research conducted for this use are Randomized Controlled Trials (RCTs), which are studies designed to evaluate patterns observed under controlled conditions. These studies examined Inapsine in adult surgical patients. Studies reported measurements of the frequency of nausea and vomiting in the time immediately following an operation. Researchers documented the requirement for additional antiemetic medication in the observed groups.

Evidence for Use in Tranquilization and Sedation

Inapsine was evaluated in research exploring its profile in achieving a defined state of sedation. This research involved RCTs and other comparative studies conducted in acute care settings. The primary goal of these trials was to examine how symptoms change over time in patients with acute agitation or severe apprehension. Outcomes related to the time to achieve a defined level of sedation and the requirement for rescue medication were evaluated. The findings describe patterns related to the time to achieve the measured sedation endpoint in the observed populations. These studies often examined comparisons of Inapsine against other agents used for sedation.

Follow-up and Duration of Study Observations

The research available for Inapsine predominantly focuses on short-term symptom changes during the acute phase of treatment. For both indications, the primary observation period in the trials was limited to the first 24 to 48 hours after the drug was observed in the study setting. Consequently, there is limited information for long-term outcomes or how the initial short-term changes might evolve over extended periods.

Key Limitations and What Remains Uncertain About Inapsine

The available research provides context for Inapsine's use, but evidence quality varies across studies. Some trials included modest sample sizes, and comparative evidence is lacking against alternative medications. Furthermore, the long-term effects are not fully established for either indication, as the follow-up durations were limited to the immediate acute phases. Overall, the research contributes to the broader evidence landscape, but there are still areas where data are still emerging, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Inapsine (FAQ)

Q: How quickly does Inapsine start working?

According to official documents, Inapsine has a rapid onset of action. Its effects, such as tranquilization, typically begin within minutes after it is administered by injection.

Q: Is Inapsine a scheduled or controlled substance?

Official drug classification documents indicate that Inapsine is not a scheduled or controlled substance under current regulations.

Q: What does 'neuroleptic' mean in the context of Inapsine?

Inapsine is classified as a neuroleptic agent. This general term refers to a class of medication that works by blocking dopamine receptors in the central nervous system. This action modifies nerve function and is related to the medication's intended use for tranquilization and anti-nausea.

Q: What is the difference between Inapsine and other similar drugs used for nausea?

Inapsine is formally categorized as a butyrophenone neuroleptic agent and a strong antiemetic. It primarily works by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) in the brain. This classification is used to describe its antiemetic activity.

Q: How does Inapsine's effect compare to promethazine for post-operative nausea?

Official literature describes Inapsine's function based on its specific classification. It is formally categorized as a butyrophenone neuroleptic agent and a strong antiemetic. Its effect is achieved by blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) in the brain.

Q: Is Inapsine still widely used today?

The use of Inapsine decreased following the issuance of the Boxed Warning in 2001. However, it continues to be utilized in acute settings by healthcare providers. Official information indicates it is commonly used for the prevention of post-operative nausea and vomiting.

Q: Is Inapsine a general anesthetic?

No, Inapsine is classified as a neuroleptic and antiemetic agent. While it is sometimes used as an adjunct (meaning, an additional component) in a general anesthesia regimen, it is not categorized as a general anesthetic drug itself.

Q: What is the difference between Inapsine and haloperidol?

Inapsine is formally categorized as a butyrophenone neuroleptic agent and a strong antiemetic. It primarily works by blocking dopamine D2 receptors in the central nervous system. This specific classification is used to describe its properties and approved uses.

Q: What are the signs of a potential overdose with Inapsine?

Official patient information describes signs of a potential overdose. These symptoms may include severe drowsiness, extremely shallow breathing, and unusual body movements such as muscle stiffness or trembling. Additionally, an irregular heartbeat is a described sign, and regulatory information notes the need for prompt evaluation.

Q: Is it documented that Inapsine can interact with herbal products?

Official guidance advises patients to inform their healthcare professional about all substances being taken. This includes all non-prescription medicines, vitamins, and supplements, as potential interactions are a factor for consideration before administration.

Q: What is the average duration of Inapsine's effect?

Official clinical pharmacology documents describe the duration of effects. The primary tranquilizing and sedative effects are generally stated to last for approximately two to four hours. However, some effects on consciousness may potentially continue for up to 12 hours.

Q: Can Inapsine be used to treat anxiety in general?

Official documents state that the medicine is used to provide tranquilization for acute agitation or severe apprehension. It is generally reserved for use in specific, acute medical settings and is not indicated for the long-term or generalized management of chronic anxiety disorders.

Q: Is Inapsine used before or after surgery?

Official indications state that Inapsine is commonly used for the prevention and treatment of nausea and vomiting. These conditions specifically occur in the period after surgical procedures, known as the post-operative period.

Q: What is the meaning of the Black Box Warning for Inapsine?

The Boxed Warning highlights the potential for serious effects on heart rhythm. This includes the risk of QT prolongation, which can lead to life-threatening heart rhythm problems like Torsades de pointes. The warning also states that the drug should be reserved for use in patients who have failed to show an acceptable response to other adequate treatments.

Q: What types of allergic reactions are associated with Inapsine?

Allergic reactions are described in official safety materials. These may include common symptoms such as a skin rash, hives, or itching. More serious signs may involve swelling of the face, lips, tongue, or throat.

Q: Why is Inapsine not used for long-term psychiatric conditions?

The medicine is not intended for long-term or chronic use. Official use is restricted to acute, short-term administration in a medically controlled setting due to the drug's safety profile and risk management strategy.

Q: Are there any known warnings about driving or operating machinery after Inapsine use?

Official documents state that Inapsine can affect coordination, judgment, or reaction time. Regulatory information advises caution regarding driving or operating machinery until the effects of the medicine are fully known.

Q: Is Inapsine considered a first-line treatment for its approved uses?

No, Inapsine is not typically considered a first-line therapy. Official documentation indicates that its use is reserved for patients who have failed to show an acceptable response to other adequate treatments.

Q: Does Inapsine have a generic version available?

Yes, a generic version of the medicine is available. The active ingredient in Inapsine is called droperidol.

How should Inapsine be stored and disposed of?

Inapsine (droperidol) Injection must be stored under specific environmental controls as detailed in regulatory documents.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection	Protect from light; keep vials in the carton until use.
Restrictions	Do not refrigerate or freeze.

Before administration, the solution must be visually inspected, and it must not be used if particulate matter or discoloration is present. As a single-dose injection, any unused portion remaining in the container must be discarded immediately. The drug must also be stored out of the sight and reach of children and pets.

Official Disposal Instructions

Expired or unused droperidol should be disposed of via an authorized drug take-back program. If a take-back option is not available, the medicine may be mixed with an undesirable substance (like coffee grounds or dirt) and placed in a sealed container before discarding it in household trash. Used needles and syringes must be placed into an FDA-cleared sharps disposal container.

Inapsine